Futsupa Co., Ltd., which promotes industrial DX utilizing AI and image analysis technology, has formed
a capital and business alliance
to jointly develop an AI agent that balances enhanced creativity and automation in research and development.
March 13, 2025
ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture, President and Representative Director: Masafumi Sugimoto) is pleased to announce that it has entered into a capital and business alliance with Futsuper Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture, Representative Director: Hiroshi Onishi, hereinafter referred to as "Futsper"). Through this alliance, Rohto will promote industrial DX (digital transformation) utilizing Futsuper's AI technology, aiming to optimize production processes and realize efficient and creative research and development using AI agents *.
* AI agent: An intelligent system that makes autonomous decisions and performs tasks under specific circumstances.
Background and purpose of the contract
Our company's management vision is "Connect for Well-being," and we conduct business that supports people's health and happiness through the research, development, manufacturing, and sales of pharmaceuticals and healthcare products. In addition to the healthcare field, we have been working towards realizing well-being in various fields such as food, community, and health and productivity management.
In recent years, manufacturing sites have faced challenges such as labor shortages and the need to improve productivity, leading to a growing demand for enhanced creativity and efficiency through the use of AI and image analysis technologies.
Futsper is a startup company that leverages AI and image analysis technology to promote labor-saving and automation in manufacturing. It aims to drive industrial digital transformation and improve the efficiency of research and development and production processes. In January 2025, Futsper welcomed Takeo Kanade (Professor at Carnegie Mellon University), a world-leading expert in the field of AI and robotics, as a technical advisor, further strengthening its technological capabilities and accelerating innovation.
Our company will invest in Hutzper, supporting its growth strategy and jointly promoting future technological innovation. This investment will enable Hutzper to further expand its business and accelerate the development of its existing AI solutions for the manufacturing industry. Furthermore, through this partnership, our company and Hutzper will jointly advance projects related to the automation and efficiency of research and development processes. By combining our knowledge and know-how in bio and chemical research and development with Hutzper's AI technology, we aim to develop an AI agent that balances enhanced creativity and automation in research and development, and enter new markets.
Mr. Kanade commented with great anticipation, "In the pharmaceutical formulation field, we believe that great possibilities can be opened up by aiming for creativity and efficiency in both research and development and manufacturing, and by incorporating the physical processes of experimentation, manufacturing, and observation using AI and robots."
Futsupa Co., Ltd. Company Information
| name |
Futsupa Co., Ltd. |
| location |
Osaka City, Osaka Prefecture |
| representative |
Hiroshi Onishi (Representative Director) |
| Establishment |
April 2020
|
| URL |
https://hutzper.com |
| Business details |
Providing industrial DX solutions utilizing AI and image analysis technologies. |
Future outlook
The impact of this matter on our consolidated financial results for the fiscal year ending March 2025 is expected to be minor, and we will promptly inform you of any further matters that need to be disclosed.